On November 4th, Lawrence voters have a choice between current mayor Brian DePena who is serving his first four-year term and challenger, hero firefighter Juan “Manny” ...

Sen. Rand Paul, R-Ky., said he will be supporting fellow liberty-minded lawmaker, Rep. Thomas Massie, R-Ky., as he faces a primary challenge from a candidate backed by President Donald Trump. Trump ...

When it comes to skin vs gravity, you'd be forgiven for assuming the outcome is a forgone conclusion (even with the best skincare arsenal at your disposal). But, according to the experts, there are in ...

CINCINNATI — Aside from learning the Pittsburgh Steelers aren’t quite running away with the AFC North just yet, here are five other items gleaned from Thursday’s 33-31 defeat at the Cincinnati Bengals ...

Kailera Therapeutics has raised $600 million to take its lead obesity program into phase 3. The series B round continues the meteoric rise of Kailera, which exited stealth with $400 million and ...

Namibia-focused Sintana Energy and Uruguay-focused Challenger Energy have agreed to an all-share deal to create an Atlantic-margin focused oil and gas exploration "champion". The news saw ...

The New York Jets keep fumbling the football. Jets head coach Aaron Glenn tried to take the blame postgame instead of it being placed on Hall and the players. “I gotta figure out a way to get our guys ...

US employers dialed back hiring plans in September and announced fewer job cuts, according to data from outplacement firm Challenger, Gray & Christmas. Companies last month announced plans to add ...

The Dallas Cowboys were coming into Week 3 with all the confidence in the world after their win over the New York Giants. Unfortunately, the Chicago Bears didn't get the memo. The Bears outclassed the ...

AI chip startup Groq confirmed Wednesday that it raised a fresh $750 million in funding at a post-money valuation of $6.9 billion. This topped the rumored numbers when word leaked in July that Groq ...

A phase 3 trial of aTyr Pharma’s efzofitimod in a lung disease has missed its primary endpoint. With a multibillion-dollar market in its sights, the biotech is planning to talk to the FDA about a path ...